
NRX Pharmaceuticals (NRXP) Stock Forecast & Price Target
NRX Pharmaceuticals (NRXP) Analyst Ratings
Bulls say
NRX Pharmaceuticals is well positioned with multiple shots on goal and increasing regulatory clarity for their CNS portfolio. With the potential for both branded and generic ketamine pathway approvals, as well as expanding their NRX-101 program into a broader neuroplastic platform, the company has shown promising progress in their clinical trials. Additionally, their recent acquisition and expansion of HOPE Therapeutics supports their long-term commercialization strategy, making NRX Pharmaceuticals a strong candidate for future growth and success in the biotech market.
Bears say
NRX Pharmaceuticals is facing significant risks related to its clinical development, regulatory approval, and commercial execution for its novel bipolar depression drugs, NRX-100 and NRX-101. The company's valuation is based on optimistic assumptions, such as a high probability of success and significant revenues from future general use. However, potential challenges such as financing and dilution risks could hinder the achievement of its $45 price target. Overall, the company's stock is a high-risk investment with uncertainties surrounding its potential success in the market.
This aggregate rating is based on analysts' research of NRX Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
NRX Pharmaceuticals (NRXP) Analyst Forecast & Price Prediction
Start investing in NRX Pharmaceuticals (NRXP)
Order type
Buy in
Order amount
Est. shares
0 shares